Table Of Content

ELSEVIER Journal of Affective Disorders (1998) 245-246 Author inde: Altshuler, L.L., see Frye, M.A. (48) 91 A functional variant of the serotonin transporter gene Asthana, H.S., Mandal, M.K., Khurana, H. and Haque-Nizamie, S families with bipolar affective disorder (48) 135 Visuospatial and affect recognition deficit in depression (48 < Féline, A., see de Bonis, M. (48) 191 Flint, T., see Ewald, H. (48) 135 Biondi, M., see Bonaccorso, S. (48) 75 Frye, M.A., Ketter, T.A., Altshuler, Ll Denicoff, K., Dunn Blumer, D., Herzog, A.G., Himmelhoch, J., Salgueiro, C.A. and R.T., Kimbrell, T.A., Cora-Locatelli, G. and Post, R.M Clozapine in bipolar disorder: treatment implications for other To what extent do premenstrual and interictal dysphoric atypical antipsychotics (48) 91 disorder overlap? significance for therapy (48) 215 S., Lin, A.-h., Verkerk, R., Van Hunsel, F., Libbrecht Goodyer, I.M., see Tamplin, A. (48) | S., DeClerck, L., Biondi, M., Janca, A. and Maes Graw, P., Haug, H.-J.. Leonhardt, G. and Wirz-Justice, A M Sleep deprivation response in seasonal affective disorder Immune markers in fibromyalgia: comparison with major during a 40-h constant routine (48) 69 depressed patients and normal volunteers (48) 75 Bowers, M.B., see Mazure, C.M. (48) 83 Hadzi-Pavlovic, D., see Manicavasagar, V. (48) 181 Bromet, E.J > Carlson, G.A Hakko, H., see Rasdnen, P. (48) 63 Burrows, G., see Perenyi, A Hanafusa, I., see Okano, T. (48) 233 Haque-Nizamie, S., see Asthana, H.S. (48) 57 Carlson, G.A., Bromet, E.J. and Jandorf, | Haug, H.-J., see Graw, P. (48) 69 Conduct disorder and mania: what does it mean in adu Hayashi, M., see Okano, T. (48) 2 YO Herbert, J., see Tamplin, A. (48) Cooke, L.B. and Thompson, ¢ Herzog, A.G., see Blumer, D. (48 Seasonal Affective Disorder and response Hildebrandt, G., see Moser, M. (48 patients with learning disability (48) 145 Himmelhoch, J., see Blumer, D. (48) ora-Locatelli, G., see Frye, M.A. (48) 91 Hoehn-Saric, R., see Moser, M. (48) Hopwood, M., see Perenyi, A. (48) 163 Boeck, P., see de Bonis, M. (48) 191 Horrobin, D., see Edwards, R. (48) 149 Bonis, M., De Boeck, P., Lida-Pulik, H., Hourtané, M. and Hourtané, M., see de Bonis, M. (48) 191 Feline, A Self-concept and mood: A comparative study between de Janca, A., see Bonaccorso, S. (48) 75 pressed patients with and without borderline personality Jandorf, L., see Carlson, G.A. (48) 199 disorder (48) 191 Judd, L.L., see Rapaport, M.H. (48) 227 DeClerck, I see Bonaccorso, S. (48) 75 Degn, B., see Ewald, H. (48) 135 Kaneko, E., see Okano, T. (48) 233 Denicoff, K., see Frye M.A. (48) 91 Ketter, T.A., see Frye, M.A. (48) 91 Dewhurst, J., see Wilhelm, K. (48) 37 Khurana, H., see Asthana, H.S. (48) 57 Dunn, R.T., see Frye, M.A. (48) 91 Kimbrell, T.A., see Frye, M.A. (48) 91 Kline Leidy, N., Palmer, C., Murray, M., Robb, J. and Revicki, Edwards, R., Peet, M., Shay, J. and Horrobin, D D.A Omega-3 polyunsaturated fatty acid levels in the diet and in Health-related quality of life assessment in euthymic and red blood cell membranes of depressed patients (48) 149 depressed patients with bipolar disorder. Psychometric per Ewald, H., Flint, T., Degn, B., Mors, O. and Kruse, T.A formance of four self report measures (48) 207 $0165-0327(97)00186-9 Author index toms: functional impairment and response to treatment (48) | ‘ 2 7 Okano Rasdnen, P., Tiithonen, J. and Hakko, H Moser, M. (48) 11 The incidence and onset-age of hospitalized bipolar affective Graw ' disorder in Finland (48) 63 Bonaccorso j Revicki, D.A., see Kline Leidy, N. (48) 20 Revicki, D.A. and Wood, M Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepres sant medications (48) 25 Robb, J., see Kline Leidy, N. (48) 207 Salgueiro, C.A., see Blumer, D. (48) 215 H.S. (48 Salokangas, R.K.R. and Poutanen, O ind Hadzi-Paviovic, D Risk factors for depression in primary care. Findings of the to risk TADEP project (48) 171 Scharpe, S., see Bonaccorso, S. (48) 75 Seidman, S.N. and Rabkin, J.G Testosterone replacement therapy for hypogonadal men with neuroleptic response SSRI-refractory depression (48) 157 Shay, J se Edwards, R. (48) 149 Silove, D., see Manicavasagar, V. (48) 181 Smeraldi, McLeod, D.R., Hil. de Amisulprf ide versus fluoxetine in Fp atients with dysthymia or es OE el major depression in partial remission. A double-blind, com parative study (48) 47 oe Steinbrenner, B., see Moser, M. (48) 115 Stewart, A Choosing an antidepressant: effectiveness based phar estimation of the onset of the macoeconomics (48) 125 Tamaki, R., see Okano, T. (48) 233 Tamplin, A., Goodyer, I1.M. and Herbert, J Family functioning and parent general health in families of adolescents with major depressive disorder (48) | Thompson, C., see Cooke, L.B. (48) 145 Tiihonen, J., see Rasanen, P. (48) 63 Kumar, R., Kaneko, I Tamaki, R M. and Matsuyama, A Vandoolaeghe, E., Van Hunsel, F., Nuyten, D. and Maes, M ind clinical investigation of postpartum Auditory event related potentials in major depression: pro Japanese mothers (48) 233 longed P300 latency and increased P200 amplitude (48) 105 Van Hunsel, F., see Bonaccorso, S. (48) 75 Kline Leidy, N. (48) 207 Van Hunsel, F., see Vandoolaeghe, E. (48) 105 Wilhelm, K. (48) 3 Verkerk, R., see Bonaccorso, S Edwards, R. (48) 149 Voica, M., see Moser, M. (48) Norman Hopwood, M. and Burrows, G ymptoms, depression and parkinsonian symptoms in Wilhelm, K., Parker, G. and Dewhurst, J alised schizophrenic patients (48) 163 Examining sex differences in the impact of anticipated and M.A. (48) 91 actual life events (48) 37 Salokangas, R.K.R. (48) 171 Wirz-Justice, A., see Graw, P. (48) 69 Wood, M., see Revicki, D.A. (48) 25 Seidman, S.N apaport, M.H. and Judd, L.I Zapotoczky, H.-G., see Moser, M. (48) 115 Minor depressive disorder and subsyndromal depressive symp ELSE Journal of Affective Disorders 48 (1998) 247-249 Subject index Admission rate; Postpartum psychiatric illness; Puerperal psycho Bipolar affective disorder; Antidepressants; Serotonin transpor sis; Epidemiology; Phenomenology 48, 233 ter protein; SERT gene 48, 135 Adolescent depression; Family functioning 48, | Bipolar Disorder; Mania; Incidence; Prevalence 48, 63 Affective discrepancy; Self-concept; Depression; Borderline 48, Bipolar disorder; Clozapine; Neuroleptics 48, 91 19] Bipolar disorder; Quality of life; Psychometric evaluation Affective symptoms; Depression; Dependency; Neuroticism; Life Measurement 48, 207 hange events; Sex differences 48, 3 Blood pressure; Cardiac vagal tone; Respiratory sinus arrhyth Affective task; Visuospatial task Major depressives Perceptual mia; Major depression; Age; Pulse wave velocity; Autonomous impairment 48, 57 heart rate 48, 115 Age; Cardiac vagal tone; Respiratory sinus arrhythmia; Major Borderline; Self-concept Affective discrepancy; Depression 48, depression Pulse wave velocits Blood pressure Autonomous 19] heart rate 48, 115 Cardiac vagal tone; Respiratory sinus arrhythmia; Major depres Amisulpride; Dysthymia; Major depression; Fluoxetine 48, 47 sion; Age; Pulse wave velocity Blood pressure Autonomous heart rate 48, 115 Androgens; Testosterone; Major depression; Refractory depres sion; Psychoendocrine; Open clinical trial 48, 157 Cell membranes; Depression; Polyunsaturated fatty acids; Phos pholipid; Diet 48, 149 Antidepressant treatment; Health state utilities; Major depres sive disorder Health status assessment Patient preferences Cellular immunity; Fibromyalgia; Neopterin; Depression; Selec Health outcomes 48, 25 tive serotonin reuptake inhibitors; Antidepressants 48, 75 Antidepressants; Onset of activity; Assessment of onset 48, 15 Clozapine; Bipolar disorder; Neuroleptics 48, 91 Antidepressants; Fibromyalgia; Neopterin; Cellular immunity Conduct disorder; Bipolar; Mania 48, 199 Depression; Selective serotonin reuptake inhibitors 48, 75 Costs; SSRIs; TCAs; Economics; Effectiveness 48, 125 Antidepressants; Depression; Event-related potential; P300 com Dementia; Depression; Event-related potential; P300 component; ponent; Fluoxetine Dementia 48, 105 Antidepressants; Fluoxetine 48, 105 Antidepressants; Bipolar affective disorder, Serotonin transporter Dependency; Affective symptoms; Depression; Neuroticism; Life protein; SERT gene 48, 135 change events; Sex differences 48, 3 Antidepressants; Minor depression, Depressive symptoms; Major Depression; Affective symptoms; Dependency; Neuroticism; Life depression pharmacology 48, 227 change events; Sex differences 48, > Anxiety; Separation anxiety; Panic disorder; Attachment 48, 181 Depression; Fibromyalgia; Neopterin; Cellular immunity; Selec Assessment of onset; Antidepressants; Onset of activity 48, 15 tive serotonin reuptake inhibitors; Antidepressants 48, 75 Attachment; SepIa ration anxiety; Panic disorder; Anxiety : 48, 181 Depression; Event-related potential; P300 component; Antide pressants; Fluoxetine; Dementia 48, 105 Autonomous heart rate; Cardiac vagal tone; Respiratory sinus urrhythmia; Major depression; Age; Pulse wave velocity; Blood Depression; Polyunsaturated fatty acids; Phospholipid; Cell mem pressure 48, 115 branes; Diet 48, 149 Bipolar; Mania; Conduct disorder 48, 199 Depression; Risk factors; Primary care 48, 171 §$0165-0327(97)00187-0 Depression; Self wderline 48, Major depression pharmacology; Minor depression; Depressive symptoms; Antidepressants 48, 227 Depressive symptoms; Sch Major depressive disorder; Health state utilities; Health status issessment; Patient preferences; Antidepressant treatment; Health nptom 48. { Depressive symptoms; Minor outcomes 48, 25 Major depressives; Visuospatial task; Affective task, Perceptual mpairment 48, 57 Mania; Bipolar Disorder; Incidence; Prevalence 48, 63 Dysthymia; M Mania; Homovanillic acid HVA) Methoxyhydrox yphenylethyleneglycol (MHPG); Neuroleptic response 48, 83 Economics; SSR Mania; Bipolar; Conduct disorder 48, 199 Effectiveness; Measurement; Quality of life; Bipolar disorder, Psychometric Epidemiology; -valuation 48, 207 I Event-related potential; Depre Methoxyhydroxyphenylethyleneglycol (MHPG); Mania Fluoxetine; De Homovanillic acid (HVA): Neuroleptic respI onse 48, 83 Family functioning; Minor depression; DepIr essive symptI oms: Major dep|r ession |y harmacology: Antidep|r essants 48, 22 Fibromyalgia; N« sants 48, 75 Negative symptoms; Schizophrenia; Depressive symptoms; Par kinsonian symptoms 48, 163 Fluoxetine; Dysthymia a lepression, Amisulpride 48, 47 Neopterin; Fibromyalgia; Cellular immunity; Depression; Selec Fluoxetine; Depre lated potential; P300 component tive serotonin reupf take inhibitors; AntidepIr essants 48, 75 D Neuroleptic response; Mania; Homovanillic acid (HVA) Health outcomes; Healt te utilities; Mi Methoxyhydroxyphenylethyleneglycol (MHPG) 48, 83 ' Healtt Patient preferen t 48, Neuroleptics; Clozapine; Bipolar disorder 48, 91 Health state utilities; Major disorder, Health status Neuroticism; Affective symptoms; Depression; Dependency; Life Patient pre treatment; Health change events; Sex differences 48, 37 48, Onset of activity; Antidepressants; Assessment of onset 48, 15 Health status assessment; Health state utilities; Major depressive Open clinical trial; Testosterone; Major depression; Androgens; lisord atient preferences; Antidepressant treatment, Health Refractory depression; Psychoendocrine 48, 157 P300 component; Depression; Event-related potential; Antide Homovanillic acid (HVA); Mania Methox yhydrox pressants; Fluoxetine; Dementia 48, 105 th eglycol (MHPG); Neuroleptic response 48, 83 Panic disorder; Separation anxiety; Anxiety; Attachment 48, 181 Incidence; Bipolar Disorder: Mania; Prevalence 48, 63 Interictal dysphoric disorder; Premenstrual dysphoric disorder Parkinsonian symptoms; Schizophrenia; Depressive symptoms I t t for affectiv lisorder of epilepsy Treatment for Negative symptoms 48, 163 ly phoria 48, 215 Patient preferences; Health state utilities; Major depressive Learning disability; Seasona Disorder, Phototherapy disorder; Health status assessment Antidepressant treatment 48, 145 Health outcomes 48, 25 Life change events; Affective sympI toms; DeprIe ssion; Dep|e nden Perceptual impairment; Visuospatial task; Affective task; Major Neuroticism; Sex differences 48, lepressives 48, 57 Major depression; Dysthymia; Fluoxetine; Amisulpride 48, 47 Phenomenology; Postpartum psychiatric illness; Admission rate Puerperal psychosis; Epidemiology 48, 233 Major depression; Cardiac vagal tone; Respiratory sinus arrhyth ia; Age; Pulse wave velocity; Blood pressure; Autonomous heart Phospholipid; Depression; Polyunsaturated fatty acids; Celi mem 48, 115 branes; Diet 48, 149 Major depression; Testosterone; Androgens; Refractory depres Phototherapy; Seasonal Affective Disorder, Learning disability Psychoendocrine; Open clinical trial 48, 15 48, 145 Subject index 249 Polyunsaturated fatty acids; Depression; Phospholipid; Cell Seasonal Affective Disorder; Learning disability; Phototherapy membranes; Diet 48, 149 48, 145 Postpartum psychiatric illness; Admission rate; Puerperal psy Selective serotonin reuptake inhibitors; Fibromyalgia; Neop chosis; Epidemiology; Phenomenology 48, 233 terin; Cellular immunity; Depression; Antidepressants 48, 75 Premenstrual dysphoric disorder; Interictal dysphoric disorder Self-concept; Affective discrepancy; Depression; Borderline 48, Treatment for affective disorder of epilepsy; Treatment for premenstrual dysphoria 48, 215 ration anxiety; Panic disorder; Anxiety; Attachment 48, 181 Prevalence; Bipolar Disorder; Mania; Incidence 48, 63 Primary care; Risk factors; Depression 48, Serotonin transporter protein; Antidepressants; Bipolar affec tive disorder; SERT gene 48, 135 Psychoendocrine; Testosterone; Major depression: Androgens Refractory depression; Open clinical trial 48, 157 SERT gene; Antidepressants; Bipolar affective disorder Serotonin transporter protein 48, 135 Psychometric evaluation; Quality life; Bipolar disorder Measurement 48, 207 Sex differences; Affective symptoms; Depression; Dependency Neuroticism; Life change events 48, 37 Puerperal psychosis; Postpartum psychiatric illness; Admission rate; Epidemiology; Phenomenology 48, 233 Sleep deprivation; Seasonal affective disorder; Response crite 48, 69 Pulse wave velocity; Cardiac vagal tone; Respiratory sinus rrhythmia; Major depression; Age; Blood pressure, Autonomous SSRIs; TCAs: Economics; Costs; Effectiveness 48, 125 heart rate 48, 115 CAs; SSRIs; Economics; Costs; Effectiveness 48, 125 Quality of life; Bipolar disorder; Psychometric evaluation; Mea Festosterone; Major depression; Androgens; Refractory depres surement 48, 207 sion; Psychoendocrine; Open clinical trial 48, 157 Refractory depression; Testosterone Major depression; An Treatment for affective disorder of epilepsy; Premenstrual ilrogens; Psychoendocrine; Open clinical trial 48, 157 dysphoric disorder; Interictal dysphoric disorder; Treatment for Respiratory sinus arrhythmia; Cardiac vagal tone Major ae premenstrual dysphoria 48, 215 pression; Age; Pulse wave velocity; Blood pressure Autonomous lreatment for premenstrual dysphoria; Premenstrual dysphoric heart rate 48, 115 disorder, Interictal dysphoric disorder; Treatment for affective Response criteria; Seasonal affective disorder; Sleep deprivation disorder of epilepsy 48, 215 48, 69 Visuospatial task; Affective task; Major depressives; Perceptual Risk factors; Depression; Primary care 48, 171 impairment 48, 57 Schizophrenia; Depressive symptoms; Negative symptoms; Par kinsonian symptoms 48, 163 Seasonal affective disorder; Sleep deprivation; Response criteria 48, 69